Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £15.50.

In this piece, we will look at where GSK plc (NYSE:GSK ... for European firms that could emanate from China. The top three of ...

GSK’s ViiV healthcare unit is countering rival HIV drugmaker Gilead’s recent global access moves with its own pledge to make at least 2 million doses of its long-acting pre-exposure prophylaxis (Pr | ...

The drug remains one of GSK's top products, with sales of £856 million ($1.1 billion) in the first half of this year, up 15%. COPD could open up a massive new market for the drug, which still has ...

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...

Specialty Medicines led the way with a 22% increase, bolstered by new oncology and HIV products. GSK's overall sales were ...

GSK’s ex-head of vaccines says its blockbuster jab for a flu-like virus that spreads in the autumn and winter is too ...

The European Medicines Agency (EMA) has started a review of popular anti-baldness and enlarged prostate medicines ...

The GSK share price has had a rotten few years and now it's heading south yet again. Investor Harvey Jones continues to hang ...

Pfizer sold a stake in British consumer healthcare group Haleon worth about $3.26 billion on Monday, cutting its shareholding ...

(Alliance News) - GSK PLC on Tuesday announced a new positive opinion from the EU's European Medicine Agency's Committee for Medicinal Products for Human Use. The London-based pharmaceutical company ...

SPANISH health chiefs have withdrawn a popular antibiotic from shelves due to a defect in the sealing of some bottles.  The ...